Annovis Bio Inc (ANVS)
NYSE:ANVS
Want to see ANVS full AI Analyst Report?
Top Page
Annovis Bio
(NYSE:ANVS)
Select Model
Select Model
Rating:42Neutral
Price Target:
$1.50
▼(-19.79% Downside)
Action:Reiterated
Date:05/21/26
The score is primarily weighed down by weak financial performance (no revenue, sustained losses, and significant cash burn/volatility). Technicals also indicate a weak trend with limited positive momentum signals, and valuation provides little support given losses and no dividend.
Positive Factors
Debt-free balance sheet
A reported zero total debt position provides structural financial flexibility and lowers fixed obligations, reducing insolvency risk while the company advances clinical programs. This improves options for strategic partnerships, licensing or selective debt use without legacy interest burdens over the next several quarters.
Negative Factors
No revenue / persistent losses
A pre-commercial profile with zero revenue and persistent, material losses means the company must rely on external funding and clinical success for long-term viability. This structural absence of operating income raises execution and financing risk over the medium term absent a successful asset outcome or partnership.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A reported zero total debt position provides structural financial flexibility and lowers fixed obligations, reducing insolvency risk while the company advances clinical programs. This improves options for strategic partnerships, licensing or selective debt use without legacy interest burdens over the next several quarters.
Read all positive factors
Annovis Bio (ANVS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$59.59M
Dividend YieldN/A
Average Volume (3M)1.25M
Price to Earnings (P/E)―
Beta (1Y)2.53
Revenue GrowthN/A
EPS Growth20.55%
CountryUS
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.72
Shares Outstanding34,646,870
10 Day Avg. Volume1,258,485
30 Day Avg. Volume1,253,908
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)4.22
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.40
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.57
Forecast
1Y Price Target
$12.50Price Target Upside568.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.6
Revenue Forecast (FY)N/A
Annovis Bio Business Overview & Revenue Model
Company Description
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials ...
How the Company Makes Money
null...
Annovis Bio Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -41.42M | -29.70M | -26.69M | -45.03M | -25.51M | -14.50M |
| Net Income | -40.92M | -28.85M | -24.59M | -56.20M | -25.33M | -14.49M |
Balance Sheet | ||||||
| Total Assets | 16.24M | 21.08M | 13.93M | 10.21M | 36.02M | 46.00M |
| Cash, Cash Equivalents and Short-Term Investments | 14.22M | 19.53B | 10.55M | 5.75M | 28.38M | 45.69M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 13.12M | 4.23M | 4.62M | 17.96M | 7.70M | 1.51M |
| Stockholders Equity | 3.13M | 16.85M | 9.31M | -7.75M | 28.32M | 44.49M |
Cash Flow | ||||||
| Free Cash Flow | -26.53M | -25.62B | -21.89B | -39.97M | -17.31M | -9.13M |
| Operating Cash Flow | -26.53M | -25.62B | -21.89B | -39.97M | -17.31M | -9.13M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 18.52M | 34.60B | 26.69B | 17.34M | 4.61K | 46.74M |
Annovis Bio Technical Analysis
Negative
1.87
Price Trends
2.00
Negative
2.29
Negative
2.58
Negative
Market Momentum
-0.08
Positive
38.05
Neutral
8.02
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANVS, the sentiment is Negative. The current price of 1.87 is below the 20-day moving average (MA) of 1.97, below the 50-day MA of 2.00, and below the 200-day MA of 2.58, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 38.05 is Neutral, neither overbought nor oversold. The STOCH value of 8.02 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ANVS.
Annovis Bio Risk Analysis
Annovis Bio disclosed 77 risk factors in its most recent earnings report. Annovis Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Annovis Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $198.80M | -2.40 | -79.63% | ― | -100.00% | -1124.16% | |
52 Neutral | $103.45M | -3.49 | -0.17% | ― | 115.44% | -1.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $166.42M | -1.86 | -81.24% | ― | -11.87% | -86.91% | |
45 Neutral | $161.79M | -1.25 | -123.07% | ― | ― | 3.91% | |
42 Neutral | $59.59M | -1.17 | -318.08% | ― | ― | 20.55% |
* Healthcare Sector Average
ANVS
Annovis Bio
1.83
-1.11
-37.76%
WHWK
Whitehawk Therapeutics
4.06
2.02
99.02%
DTIL
Precision BioSciences
6.17
1.14
22.66%
GLSI
Greenwich LifeSciences
23.03
13.56
143.19%
ABOS
Acumen Pharmaceuticals
2.37
1.23
107.89%
COYA
Coya Therapeutics, Inc.
4.64
-0.73
-13.59%
Annovis Bio Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Annovis Bio Announces Dilutive Equity Offering for Trials
Negative
May 20, 2026
On May 20, 2026, Annovis Bio entered an underwriting agreement with Canaccord Genuity for a public offering of 7,895,000 common shares and accompanying warrants to purchase up to 7,105,500 shares, priced at a combined $1.90 per share and nine-tent...
Business Operations and StrategyPrivate Placements and Financing
Annovis Bio Prices Registered Direct Offering to Fund Trials
Positive
Apr 10, 2026
On April 9, 2026, Annovis Bio priced an underwritten registered direct offering of 5,263,156 shares of common stock, together with accompanying warrants to purchase an equal number of shares, at a combined price of $1.90 per share and warrant. The...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.